SR ONE CAPITAL MANAGEMENT, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001910264

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth Tilt how tags are computed

Q2 2026 · 15 positions · Total reported value $1.04B · Top-10 concentration 95.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 17.6% · 2 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, SR ONE CAPITAL MANAGEMENT, LP disclosed 15 equity positions with a combined reported value of $1.04B. The filing implies a focused portfolio: its ten largest positions account for 95.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were MANE ($295.29M), ZBIO ($127.86M), CRSP ($111.19M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+29.4pp) and away from Other (-29.4pp).

Versus the prior quarter, SR ONE CAPITAL MANAGEMENT, LP opened 2 new positions, trimmed 1 and fully exited 0, a turnover rate of 17.6% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q2 2026 were AVLN ($108.92M), ODTX ($71.00M), MOBI ($26.61M).

Of the 2 positions fully exited versus the prior quarter, the largest were ACLX ($269.44M), ORKA ($21.11M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • AVLN AVALYN PHARMACEUTICALS INC · $108.92M
  • ODTX ODYSSEY THERAPEUTICS INC · $71.00M
  • MOBI MOBIA MED INC · $26.61M

Fully Exited (vs previous quarter)

  • ACLX ARCELLX INC · prev qtr: $269.44M
  • ORKA ORUKA THERAPEUTICS INC · prev qtr: $21.11M

Insider Transactions (Form 4)

Latest SR ONE CAPITAL MANAGEMENT, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

SR One Capital Management is an SEC-registered 13F filer based in Redwood City, CA, United States. As of Q3 2026 it reported 17 US equity positions with a combined value of $1.15B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: REDWOOD CITY, CA, United States
  • SEC registration: 801-119142 (status: Approved), registered 2020-07-24
  • Regulatory AUM (Form ADV): $2.44B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 19 private funds
  • Website: srone.com

Portfolio Structure

  • 17 positions · $1.15B reported value (Q3 2026)
  • Top 10 holdings = 94.0% of reported value
  • Largest position: MANE (VERADERMICS INC) at 21.9%
  • Average position size: $67.62M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 1 reduced
  • 14 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The rebalancing in 2026-Q2 appears to reflect a conservative approach with a focus on maintaining positions in health care sector investments. The lack of significant changes in positions suggests a market view that is either neutral or slightly positive on the health care sector. 2. Key Moves: - New Holdings: The fund added three new positions in Avalyn Pharma (AVLN), Odyssey Therapeutics (ODTX), and Oric Pharmaceuticals (ORIC). - Increased Positions: Oric Pharmaceuticals (ORIC) saw an increase of 2.2% in its share count, indicating a possible increase in the fund's confidence in the company. - No Reductions: There were no reported reductions in share count for any holdings, indicating a defensive stance with an intention to hold onto current investments. 3. Portfolio Structure: - Passive/Active: The rebalancing is largely passive, with a focus on maintaining existing positions rather than actively seeking new opportunities. - Sector Bias: The portfolio is heavily biased towards the health care sector, which is reflected in the high weightings of various health care stocks. - Risk Appetite: The risk appetite seems moderate, with a preference for stability and growth within the health care sector. 4. Per-Holding One-Liner: - MANE: Veradermics Inc. Common Stock, a biopharmaceutical company focusing on dermatology. - ZBIO: Zenas Biopharma Inc., a clinical-stage biopharmaceutical company. - CRSP: Crispr Therapeutics AG, a gene-editing biotechnology company. - AVLN: Avalyn Pharma Inc., a biopharmaceutical company focusing on orphan and rare diseases. - DSGN: Design Therapeutics Inc., a clinical-stage biotechnology company. - ODTX: Odyssey Therapeutics Inc., a biotechnology company focused on developing treatments for neurological disorders. - ALMS: Alumis Inc., a biotechnology company developing therapies for cancer. - ORIC: Oric Pharmaceuticals Inc., a biopharmaceutical company focused on the development of targeted cancer therapies. - MLYS: Mineralys Therapeutics Inc., a biopharmaceutical company. - SPRY: Ars Pharmaceuticals Inc., a biopharmaceutical company focusing on oncology. 5. One-Sentence Style Summary: SR ONE Capital Management maintained a conservative stance in the 2026-Q2 rebalancing, focusing on health care sector investments with a few new additions and no reductions, reflecting a stable and sector-specific investment strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.40M $295.29M 28.42%
28.42%
Hold
2 5.04M $127.86M 12.31%
12.31%
Hold
3 2.04M $111.19M 10.70%
10.70%
Hold
4 3.31M $108.92M 10.48%
10.48%
New
5 6.53M $94.44M 9.09%
9.09%
Hold
6 3.79M $71.00M 6.83%
6.83%
New
7 1.96M $55.15M 5.31%
5.31%
Hold
8 4.62M $49.98M 4.81%
4.81%
Add
9 1.56M $42.20M 4.06%
4.06%
Hold
10 4.01M $32.14M 3.09%
3.09%
Hold
11 1.99M $26.61M 2.56%
2.56%
New
12 3.33M $9.43M 0.91%
0.91%
Hold
13 641.02K $8.89M 0.86%
0.86%
Hold
14 137.75K $4.60M 0.44%
0.44%
Hold
15 747.75K $1.29M 0.12%
0.12%
Hold

FAQ

What did SR ONE CAPITAL MANAGEMENT, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, SR ONE CAPITAL MANAGEMENT, LP reported 15 equity positions worth $1.04B in aggregate; its largest disclosed positions were MANE ($295.29M), ZBIO ($127.86M), CRSP ($111.19M).

How large is SR ONE CAPITAL MANAGEMENT, LP's portfolio?

SR ONE CAPITAL MANAGEMENT, LP reported $1.04B of long equity holdings across 15 positions as of 2026-Q2. Top-10 holdings account for 95.1% of reported value.

What is SR ONE CAPITAL MANAGEMENT, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/sr-one-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →